Evidence map›Paper›PMID 37873342›Full record

ArticlebioRxiv : the preprint server for biology2024

Remyelination protects neurons from DLK-mediated neurodegeneration.

Greg J Duncan, Sam D Ingram, Katie Emberley, Jo Hill, Christian Cordano, Ahmed Abdelhak, Michael McCane, Jennifer E Jenks, Nora Jabassini, Kirtana Ananth and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Greg J DuncanDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.ORCID 0000-0003-0203-9972
Sam D IngramDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Katie EmberleyDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Jo HillDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR, 97239, USA.
Christian CordanoWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Ahmed AbdelhakWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Michael McCaneDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Jennifer E JenksDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Nora JabassiniWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Kirtana AnanthWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Skylar J FerraraDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR, 97239, USA.
Brittany StedelinDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Benjamin SivyerDepartment of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, 97239, USA.
Sue A AicherDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR, 97239, USA.
Thomas ScanlanDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR, 97239, USA.
Trent A WatkinsWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Anusha MishraDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Jonathan W NelsonDivision of Nephrology and Hypertension, School of Medicine, Oregon Health & Science University, Portland, OR, 97239, USA.
Ari J GreenWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, 94158, USA.
Ben EmeryDepartment of Neurology, Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR, 97239, USA.
Oregon Health & Science University · USUniversity of California, San Francisco · USUniversity of Southern California · US

Funding

Ultrastructure and Single Particle Microscopy CoreP30NS061800 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI AICHER, SUE A · 2009 to 2020
$6.6M
Neuronal responses to chronic demyelinationR01NS120981 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI EMERY, BEN · 2021 to 2025
$2.1M
MOLECULAR DISSECTION OF THE AXONAL INJURY RESPONSE FOR REGENERATION AND NEUROPROTECTIONR01NS112691 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WATKINS, TRENT · 2020 to 2024
$1.9M
Renal Pericytes as a Target for Angiotensin II Signaling in HypertensionK01DK121737 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NELSON, JONATHAN W · 2020 to 2024
$669k
NIDDK NIH HHS K01 DK121737NINDS NIH HHS P30 NS061800NINDS NIH HHS R01 NS112691NINDS NIH HHS R01 NS120981
6 · The paper itself

Abstract

Chronic demyelination and oligodendrocyte loss deprive neurons of crucial support. It is the degeneration of neurons and their connections that drives progressive disability in demyelinating disease. However, whether chronic demyelination triggers neurodegeneration and how it may do so remain unclear. We characterize two genetic mouse models of inducible demyelination, one distinguished by effective remyelination and the other by remyelination failure and chronic demyelination. While both demyelinating lines feature axonal damage, mice with blocked remyelination have elevated neuronal apoptosis and altered microglial inflammation, whereas mice with efficient remyelination do not feature neuronal apoptosis and have improved functional recovery. Remyelination incapable mice show increased activation of kinases downstream of dual leucine zipper kinase (DLK) and phosphorylation of c-Jun in neuronal nuclei. Pharmacological inhibition or genetic disruption of DLK block c-Jun phosphorylation and the apoptosis of demyelinated neurons. Together, we demonstrate that remyelination is associated with neuroprotection and identify DLK inhibition as protective strategy for chronically demyelinated neurons.

Indexed as

c-JundemyelinationDLKmicrogliamultiple sclerosisMyelinMyrfneurodegenerationoligodendrocyteremyelination

Identifiers

PMID37873342
PMCPMC10592610
OpenAlexW4387246438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.